US Pharma MarketingIncyte
Incyte CEO Bill Meury acquires Vega Therapeutics for up to $2B, adding Phase 3 von Willebrand disease drug as Jakafi faces 2028 patent cliff. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos.
Now, he’s the one buying.
In his first acquisition ...
Source: Endpoints News